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ABSTRACT
 
Objectives:
 
The development of a probabilistic Markov
model with a time horizon of 1 year to compare the cost-
effectiveness of three bronchodilators: 1) the new long-
acting anticholinergic tiotropium; 2) the short-acting
anticholinergic ipratropium; and 3) the long-acting beta
2-agonist salmeterol, for the treatment of patients with
chronic obstructive pulmonary disease (COPD) in differ-
ent countries. In this article we compare the Netherlands
and Canada.
Methods: The Markov model was structured along dis-
ease severity states and exacerbations. Transition pro-
babilities between disease states and exacerbation
probabilities were derived from patient-level data from
six randomized controlled trials assessing the efﬁcacy and
safety of tiotropium. Resource utilization during exacer-
bations and maintenance treatment for the Netherlands
were derived from two clinical trials, whereas for Canada
these data were obtained from a countrywide observa-
tional study that used similar inclusion criteria as the
trials. Second-order Monte Carlo simulations were under-
taken in which values were randomly drawn from distri-
butions of these parameters. Outcomes of the model are
yearly treatment costs, exacerbations, and quality-
adjusted life months.
Results: The mean difference in the number of exacer-
bations was 0.17 (95% uncertainty interval: -0.02–
0.37) in favor of tiotropium when compared with salm-
eterol and the difference between salmeterol and iprat-
ropium was 0.12 (-0.17–0.44) in favor of salmeterol.
The number of quality-adjusted life months did not sub-
stantially differ between treatment groups and varied
from 8.42 (SE 0.41) in the tiotropium group to 8.17
(0.46) in the salmeterol group and 8.11 (0.50) in the
ipratropium group. In the Netherlands, costs in the tio-
tropium group were 42€ (-484–353) lower than in the
salmeterol group, whereas costs in the salmeterol group
were 128€ (-795–457) lower than in the ipratropium
group. In Canada, costs were consistently lower than in
the Netherlands and nearly the same in all treatment
groups. Differences between the two countries were pri-
marily a result of a higher length of hospital stay in case
of an exacerbation in the Netherlands. The cost-
effectiveness acceptability frontier of exacerbations
showed that tiotropium was associated with the maxi-
mum expected net beneﬁt for all values of the ceiling
ratio above 0€ (the Netherlands) and 10€ (Canada) in
the base case analysis.
Conclusions: This probabilistic model-based economic
evaluation demonstrates how clinical trial data can be
combined and integrated with country-speciﬁc informa-
tion about resource utilization and unit cost to assess the
cost-effectiveness of bronchodilators in COPD patients.
Quality-adjusted life months did not substantially differ
between treatment groups. In terms of exacerbations, tio-
tropium was associated with maximum expected net ben-
eﬁt for plausible values of the ceiling ratio. In sensitivity
analyses, this outcome was most sensitive to changes in
exacerbation rates.
Keywords: COPD, economic evaluation, international
comparison, ipratropium, salmeterol, tiotropium.
 
Introduction
 
Chronic obstructive pulmonary disease (COPD) is
characterized by chronic airﬂow limitation that is
usually slowly progressing and not fully reversible
[1]. The major environmental risk factor is smok-
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ing. The airﬂow limitation in COPD is associated
with symptoms of chronic cough, sputum produc-
tion, and dyspnea upon exertion, leading to signif-
icant impairments in exercise capacity and quality
of life [1]. It has also been shown that a decreased
pulmonary function is associated with a higher fre-
quency [2] and more severe exacerbations [3,4]. In
turn, exacerbations have also been shown to con-
tribute to a more rapid decline in lung function [5],
increased morbidity, and a reduced quality of life
[6].
The global burden of COPD is expected to
increase substantially within the next decades. In
developed countries, this increase is strongly asso-
ciated with aging of the population and increased
use of tobacco in the past [7,8]. Recent studies have
shown that exacerbations contribute to approxi-
mately 35% to 45% of the total costs of COPD
treatment in the Netherlands [9], Sweden [4], and
Spain [10], and that exacerbations associated with a
hospitalization contributed to approximately 90%
of the total costs of exacerbations [9]. Although
COPD is increasingly recognized as a multifaceted
disease requiring a multidisciplinary approach, with
treatment goals focusing on smoking cessation,
improving lung function, increasing exercise capac-
ity, preventing exacerbations, and optimizing nutri-
tion, the cornerstone of COPD treatment remains
bronchodilation and adequate treatment of
exacerbations.
Recently, the inhaled anticholinergic bronchodi-
lator tiotropium has been approved by health
authorities and became available in many countries.
With duration of action of at least 24 hours, tiotro-
pium is dosed once daily. In a series of clinical trials,
tiotropium has been compared with: 1) ipratro-
pium, an anticholinergic with a recommended dos-
ing of four times daily; 2) salmeterol, a long-acting
inhaled beta-agonist with a recommended dosing of
two times daily; and 3) placebo. Tiotropium has
been shown to provide sustained bronchodilation,
improvements in dyspnea and health-related quality
of life assessed with a disease-speciﬁc instrument,
and is associated with fewer exacerbations than
ipratropium and placebo [11,12]. Improvements in
lung function with tiotropium have been shown to
be signiﬁcantly better than with salmeterol [13]. All
clinical trials were multicenter studies conducted in
a total of 19 countries.
To assess the cost-effectiveness of tiotropium in
individual countries we developed a Markov model
that integrates patient-level data from the afore-
mentioned clinical trials. This probabilistic model
allows to fully explore the uncertainty around the
cost-effectiveness estimate by applying distributions
to model parameters. The model is especially
designed to be populated with country-speciﬁc
treatment patterns and unit cost. This was done to
inform local reimbursement authorities about the
cost-effectiveness of tiotropium. In this article,
the results for the Netherlands and Canada are
presented.
 
Methods
 
The Tiotropium Trials
 
The safety and efﬁcacy of tiotropium was studied in
a number of multicenter, randomized double-blind,
double dummy, parallel group trials comparing tio-
tropium (18 
 
m
 
g qd) with either ipratropium (40 
 
m
 
g
qid), salmeterol (50 
 
m
 
g bid) or placebo. The two
ipratropium-controlled studies were conducted in
the Netherlands and Belgium, the two salmeterol-
controlled studies in North America, Australia,
Europe, and South Africa, and the two placebo-
controlled studies in the United States. All studies
were conducted in patients with COPD who were
required to be relatively stable, to have moderate to
severe airﬂow obstruction with a forced expiratory
volume in 1 second (FEV
 
1
 
) 
 
£
 
 65% (salmeterol-
controlled trials 
 
£
 
60%) of predicted normal and an
FEV
 
1
 
 
 
£
 
 70% of forced vital capacity. The duration
of the ipratropium- and placebo-controlled trials
was 1 year whereas the duration of the salmeterol-
controlled trials was 6 months. Details of the trials
including the results on lung function parameters,
quality of life, and dyspnea as well as exacerbations
and hospitalizations have been published elsewhere
[11–13].
 
Model Structure
 
The Markov model was structured around disease
states and exacerbations based on patient-level data
derived from the trials described above (Fig. 1).
Patients were classiﬁed into disease severity states
based on the pulmonary function as measured by
prebronchodilator FEV
 
1
 
 as percentage of predicted
normal, using the same severity classiﬁcation as
the updated GOLD criteria (2003): moderate
COPD (50% 
 
<
 
 FEV
 
1
 
% pred. 
 
<
 
 80%), severe COPD
(30% 
 
<
 
 FEV
 
1
 
% pred. 
 
£
 
 50%) and very severe
COPD (FEV
 
1
 
% pred. 
 
<
 
 30%) [1]. At the start of the
model simulation, 25% of the patients were
assumed to have moderate disease, 50% severe dis-
ease, and 25% very severe disease. Because patients
with mild COPD (FEV
 
1
 
% pred. 
 
>
 
 80%) were
excluded from tiotropium’s clinical trial program,
this disease state was not included in the model. In
 Oostenbrink et al.
 
34
 
addition, a death state was not included in this 1-
year model, because of the small numbers of deaths
within the trial periods (2.3%, 1.1%, and 0.2% in
the ipratropium-, salmeterol-, and placebo-
controlled studies, respectively). During each
Markov cycle, patients in each treatment group
were assigned a probability of transitioning from
one disease state to another. Depending on treat-
ment group and disease state, patients were also
assigned a probability to experience a severe or non-
severe exacerbation. In each clinical trial, an exac-
erbation was deﬁned as a complex of respiratory
symptoms (i.e., new onset or worsening of more
than one symptom such as cough, sputum, dyspnea,
or wheeze) lasting for at least 3 days. Exacerbation
severity was based on physicians’ assessments of the
intensity of an adverse event, a classiﬁcation that
was used in all trials. Nonsevere exacerbations were
deﬁned as “an awareness of a sign or symptom
which was easily tolerated” (mild intensity) or as
“discomfort enough to cause interference with
usual activity” (moderate intensity). A severe exac-
erbation was deﬁned as “incapacitating or inability
to do work or usual activity.”
To model the improvement in pulmonary func-
tion that was observed in all treatment groups dur-
ing the ﬁrst few days of the clinical trial, the length
of the ﬁrst cycle was set at 8 days. The length
of the subsequent cycles was 1 month. A period of
1 month was chosen to incorporate the full effect of
an exacerbation in terms of resource use and quality
of life on the one hand, and to minimize the risk of
experiencing more than one exacerbation during
the same cycle, which was not possible in the model,
on the other hand. Transitions between states were
assumed to take place halfway through the cycle.
The time horizon of the model was 1 year.
In the current analysis we compared tiotropium,
salmeterol, and ipratropium. Although data from
the placebo-controlled trials were used to derive
transition and exacerbation probabilities for the tio-
tropium arm, the placebo arm was not included in
the model. This was done because the placebo arm
in the clinical trials does not reﬂect usual care in
practice, because concomitant use of anticholiner-
gics and long-acting beta-agonists was not permit-
ted. In total, data in our model were based on 1296
patients treated with tiotropium, 405 patients
treated with salmeterol, and 175 patients treated
with ipratropium.
 
Transitions between Disease States
 
At each scheduled follow-up visit during the trial all
patients were assigned to one of the three disease
states, based on their prebronchodilation FEV
 
1
 
 val-
ues (
 
=
 
 trough FEV1; the primary endpoint of the
clinical trials). In all trials, we observed an initial
improvement in pulmonary function between treat-
ment initiation and the ﬁrst follow-up visit. Subse-
quent to this initial improvement, the change in
pulmonary function over time in each treatment
group remained fairly constant. Consequently, for
all treatment groups in all trials, two matrices of
transition probabilities were determined: one tran-
sition matrix for the ﬁrst cycle based on the differ-
ence between the frequency distributions of disease
states at baseline and the ﬁrst follow-up visit and a
second transition matrix for the subsequent cycles,
which is based on the difference between the fre-
quency distributions of disease states at the ﬁrst and
last follow-up visit of the trials. These transition
matrices were converted to identical time periods of
8 days (ﬁrst cycle) and 1 month (subsequent cycles)
using a Taylor series expansion. In the base-case
analysis, transition probabilities for the tiotropium
arm were estimated using the combined data from
all six clinical trials. Transition probabilities for the
comparator arms were then calculated, based on the
relative difference to tiotropium as found in the
individual trials. For example, the ipratropium-con-
trolled trials showed that the probability to move
from moderate to severe COPD was 2.7 times
greater for ipratropium than for tiotropium. Hence,
the pooled probability to transition from moderate
to severe COPD for all tiotropium patients across
the 3 trials was multiplied with 2.7 to obtain the
transition probability for ipratropium. The result-
ing sets of transition parameters are presented in
Table 1. In a ﬁnal step, a Dirichlet distribution [14]
was assigned to these input parameters and a Monte
Carlo simulation was performed in which values
were randomly drawn from these distributions. Fur-
ther details are provided in the appendix and the
 
Figure 1
 
Graphical presentation of  the Markov model.
No exacerbation
Nonsevere exacerbation
Severe exacerbation
Moderate  COPD
No exacerbation
Nonsevere exacerbation
Severe exacerbation
Severe  COPD
No exacerbation
Nonsevere exacerbation
Severe exacerbation
Very severe  COPD
For each treatment armCOPD
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paragraph “Analysis” below. To extend the time-
horizon of the model to 1 year, it was assumed
that the monthly transitions for the salmeterol-
controlled trials also applied to the period beyond
the 6-month trial period.
 
Exacerbations
 
The observed numbers of severe and nonsevere
exacerbations within each treatment arm and dis-
ease state at each trial visit were used to derive exac-
erbation probabilities. In the base-case analysis,
exacerbation probabilities in the tiotropium arm
were based on combined data from all six trials,
whereas the calculation of exacerbation probabili-
ties for the comparator arms were based on the
relative difference to tiotropium as found in the
individual trials (Table 1). Details of the calcula-
tions are provided in the appendix. It was assumed
that patients could only have one exacerbation dur-
ing each cycle. This assumption was justiﬁed by the
clinical trial data in which the risk of having more
than one exacerbation in 1 month was found to be
very small.
 
Utilities
 
Utility values per disease state were based on
empiric data from an observational study in
patients with COPD classiﬁed into the GOLD
stages [15]. Mean (SE) EQ-5D index scores for
moderate, severe, and very severe COPD were
reported to be 0.755 (0.031), 0.748 (0.06), and
0.549 (0.104), respectively. During cycles in which
patients experienced an exacerbation, it was
assumed that the utility value was reduced by 15%
in case of a nonsevere exacerbation [16] and by
50% in case of a severe exacerbation [17].
 
Resource Use and Unit Costs
 
Resource use was assigned to maintenance therapy
according to disease severity state and to severe and
nonsevere exacerbations. With the exception of the
acquisition cost for each study medication, the costs
of maintenance therapy per disease severity state
and the cost per severe and nonsevere exacerbation
were assumed to be the same for each treatment
group.
 
The Netherlands.
 
Resource use for the Netherlands
was obtained from an economic evaluation that was
piggybacked to the ipratropium-controlled trials.
The economic evaluation was based on data from
519 patients of whom 445 (86%) were Dutch.
Almost all resource use associated with mainte-
nance therapy and exacerbations could be derived
 
Ta
bl
e 
1
 
M
ea
n 
(S
E)
 d
is
ea
se
 s
ta
te
 t
ra
ns
iti
on
 a
nd
 e
xa
ce
rb
at
io
n 
pr
ob
ab
ili
tie
s*
 
Fr
om
 T
o 
 
ﬁ
ﬂ
 
D
is
ea
se
 s
ta
te
 t
ra
ns
iti
on
 p
ro
ba
bi
lit
ie
s
Ex
ac
er
ba
tio
n 
pr
ob
ab
ili
tie
s 
Fi
rs
t 
cy
cl
e 
(8
 d
ay
s)
Su
bs
eq
ue
nt
 c
yc
le
s 
(p
er
 m
on
th
)
Pe
r 
m
on
th
 
M
od
er
at
e
Se
ve
re
Ve
ry
 s
ev
er
e
M
od
er
at
e
Se
ve
re
Ve
ry
 s
ev
er
e
Ex
ac
er
ba
tio
n
Se
ve
re
 e
xa
ce
rb
at
io
n
 
†
 
 
T
io
tr
op
iu
m
M
od
er
at
e
0.
90
7 
(0
.0
18
)
0.
09
2 
(0
.0
18
)
0.
00
1 
(0
.0
02
)
0.
95
7 
(0
.0
10
)
0.
04
0 
(0
.0
10
)
0.
00
3 
(0
.0
03
)
0.
05
1 
(0
.0
04
)
0.
09
7 
(0
.0
24
)
Se
ve
re
0.
25
9 
(0
.0
17
)
0.
71
6 
(0
.0
18
)
0.
02
5 
(0
.0
06
)
0.
02
3 
(0
.0
06
)
0.
95
4 
(0
.0
08
)
0.
02
3 
(0
.0
06
)
0.
07
5 
(0
.0
03
)
0.
13
6 
(0
.0
18
)
Ve
ry
 s
ev
er
e
0.
01
0 
(0
.0
05
)
0.
34
1 
(0
.0
24
)
0.
64
9 
(0
.0
24
)
0.
00
1 
(0
.0
02
)
0.
04
5 
(0
.0
12
)
0.
95
4 
(0
.0
12
)
0.
09
6 
(0
.0
05
)
0.
19
2 
(0
.0
27
)
Sa
lm
et
er
ol
M
od
er
at
e
0.
90
0 
(0
.0
33
)
0.
10
0 
(0
.0
33
)
0.
00
1 
(0
.0
01
)
0.
92
8 
(0
.0
24
)
0.
06
6 
(0
.0
24
)
0.
00
5 
(0
.0
07
)
0.
05
7 
(0
.0
13
)
0.
03
0 
(0
.0
31
)
Se
ve
re
0.
20
1 
(0
.0
28
)
0.
76
6 
(0
.0
30
)
0.
03
3 
(0
.0
13
)
0.
02
3 
(0
.0
10
)
0.
91
8 
(0
.0
19
)
0.
05
9 
(0
.0
17
)
0.
08
9 
(0
.0
11
)
0.
13
8 
(0
.0
33
)
Ve
ry
 s
ev
er
e
0.
00
1 
(0
.0
01
)
0.
30
2 
(0
.0
42
)
0.
69
8 
(0
.0
42
)
0.
00
6 
(0
.0
08
)
0.
03
6 
(0
.0
19
)
0.
95
8 
(0
.0
21
)
0.
10
4 
(0
.0
16
)
0.
20
7 
(0
.0
48
)
Ip
ra
tr
op
iu
m
M
od
er
at
e
0.
73
9 
(0
.0
90
)
0.
25
7 
(0
.0
89
)
0.
00
4 
(0
.0
13
)
0.
92
3 
(0
.0
49
)
0.
07
3 
(0
.0
48
)
0.
00
3 
(0
.0
11
)
0.
08
0 
(0
.0
20
)
0.
26
7 
(0
.1
14
)
Se
ve
re
0.
10
2 
(0
.0
28
)
0.
84
2 
(0
.0
34
)
0.
05
6 
(0
.0
22
)
0.
01
3 
(0
.0
11
)
0.
95
0 
(0
.0
21
)
0.
03
7 
(0
.0
18
)
0.
09
7 
(0
.0
13
)
0.
18
8 
(0
.0
41
)
Ve
ry
 s
ev
er
e
0.
00
5 
(0
.0
11
)
0.
22
0 
(0
.0
65
)
0.
77
5 
(0
.0
66
)
0.
00
3 
(0
.0
09
)
0.
02
5 
(0
.0
26
)
0.
97
2 
(0
.0
27
)
0.
10
2 
(0
.0
22
)
0.
18
6 
(0
.0
62
)
 
*P
ar
am
et
er
s 
of
 th
e 
di
st
rib
ut
io
ns
 a
re
 th
e 
nu
m
be
rs
 o
f p
at
ie
nt
s 
tr
an
si
tio
ni
ng
 b
et
w
ee
n 
di
se
as
e 
st
at
es
 a
nd
 th
e 
nu
m
be
r 
of
 m
on
th
s 
w
ith
/w
ith
ou
t e
xa
ce
rb
at
io
ns
. F
or
 e
as
e 
of
 in
te
rp
re
ta
tio
n 
th
is
 T
ab
le
 p
re
se
nt
s 
th
e 
ex
pe
ct
ed
 v
al
ue
s 
(p
ro
ba
bi
lit
ie
s)
an
d 
th
e 
as
so
ci
at
ed
 s
ta
nd
ar
d 
er
ro
rs
 r
at
he
r 
th
an
 t
he
se
 n
um
be
rs
. P
ro
ba
bi
lit
ie
s 
ca
n 
be
 r
ec
al
cu
la
te
d 
in
to
 n
um
be
rs
 u
si
ng
 m
et
ho
d-
of
-m
om
en
ts
 ﬁ
tt
in
g 
[2
0]
. F
or
 t
he
 t
ra
ns
iti
on
s 
be
tw
ee
n 
di
se
as
e 
st
at
es
, D
iri
ch
le
t 
di
st
rib
ut
io
ns
 a
re
 a
ss
ig
ne
d,
 fo
r
th
e 
ris
k 
of
 e
xa
ce
rb
at
io
ns
, b
et
a-
di
st
rib
ut
io
ns
 a
re
 u
se
d.
 
†
 
G
iv
en
 a
n 
ex
ac
er
ba
tio
n,
 p
ro
ba
bi
lit
y 
th
at
 it
 is
 s
ev
er
e.
 Oostenbrink et al.
 
36
 
from these data. The details of this economic eval-
uation and the collection of resource use data and
the attached unit costs have been described else-
where [9,18]. Only those estimates likely to be inﬂu-
enced by the trial setting, like regular follow-up
visits to a general practitioner (GP) or respiratory
physician were derived from the Dutch guidelines
for the treatment of COPD patients by general prac-
titioners. Unit costs of study medications were
based on list prices and included value added taxes
and a markup of 6.02
 
€
 
 per prescription to cover
pharmacist fees. The price of ipratropium was
based on the average price of the metered dose
inhaler (MDI) and the dry powder inhaler (DPI),
weighted by the actual use of these administration
devices in the Netherlands in 2001 (44% MDI vs.
56% DPI).
Canada. COPD-related resource utilization was
collected in a prospective, Canada-wide, 52-week,
multicenter, observational study of patients with
similar inclusion criteria as the tiotropium trials,
conducted between June 2001 and September 2002.
Approximately 76% (42) of the centers were run by
general or family practitioners and 24% (13) were
run by respirologists. In total, resource utilization
data were collected from 598 patients. For the use
of maintenance medication, it was assumed that
medications patients were taking at baseline were
continued throughout the year with a compliance
rate of 80%. Because the study only recorded data
regarding physician visits in the case of exacerba-
tions, regular physician visits were collected from a
survey among 69 physicians (both specialists and
GPs) conducted in 2002. Because the deﬁnition of
exacerbation severity as used in the tiotropium clin-
ical trials was not feasible for an observational
study in a naturalistic setting, all exacerbations
associated with a hospital admission or emergency
room visit were classiﬁed as severe. Unit costs of
(study) medications were derived from the Ontario
Drug Beneﬁt Formulary (Comparative Drug Index)
and included the authorized markup (10%) and the
pharmacist current dispensing fees (3.97€, CAD
6.47€). Minimum patient copayment was sub-
tracted from the cost of a 30-day-claim. Because the
DPI device is not available in Canada, the price of
ipratropium was based on the MDI price.
The resulting resource use and unit costs for Can-
ada and the Netherlands are presented in Table 2.
Costs were determined from a health-care perspec-
tive and included all costs relevant to the Dutch and
Canadian health-care budgets. All costs are
reported in 2001 values expressed in Euros (1 Cana-
dian dollar = 0.62 Euro, exchange rate April 2004).
Discounting was not applied in this 1-year model.
 
Analysis
 
To assess the uncertainty around the point estimates
of costs, effects, and cost-effectiveness, the model
was designed probabilistically adopting the meth-
odology proposed by Briggs et al. [19,20]. Uncer-
tainty around transitions between disease states,
exacerbations, utilities, and resource use was con-
sidered simultaneously and input parameters were
entered into the model as prespeciﬁed distributions.
As proposed by Price and Briggs, we adopted a
Dirichlet distribution for transitions between dis-
ease states [14], beta distributions for exacerbations
and utilities, and a gamma distribution for the esti-
mation of resource use [21]. Second-order Monte
Carlo simulations were undertaken in which values
were randomly drawn from these distributions. The
current analysis was based on 5000 simulations.
Main outcomes of the model were the mean, SE,
being the standard deviation across the simulations,
and 95% uncertainty intervals (UI) of the costs per
patient per year, the number of exacerbations and
quality-adjusted life months. The presentation of
paired differences between treatment groups (tio-
tropium vs. salmeterol and salmeterol vs. ipratro-
pium) is based on the hierarchy of observed
outcomes. The uncertainty around costs and effects
was further explored by means of incremental cost-
effectiveness planes and separate acceptability
curves per treatment based on the net beneﬁt
approach [22].
 
Sensitivity Analysis
 
In a ﬁrst set of sensitivity analyses, the robustness of
the model for alternative transition and exacerba-
tion probabilities were investigated. In these sensi-
tivity analyses (SA1 to SA3), transitions and
exacerbations for tiotropium were based on
observed values from the ipratropium-controlled
(SA1), salmeterol-controlled (SA2), and placebo-
controlled trials (SA3) separately, instead of the
combined data from all six trials. Transitions and
exacerbations for the comparator arms were calcu-
lated based on the relative difference to tiotropium
as found in the individual trials. In two additional
sensitivity analyses (SA4 and SA5), we investigated
the separate contribution of exacerbation probabil-
ities and disease state transitions to the outcomes of
the model by assuming that either transition prob-
abilities (SA4) or exacerbation probabilities (SA5)
did not differ between treatment groups. In a third
 Economic Evaluation of Bronchodilator Therapy
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set of sensitivity analyses (SA6 to SA8), we varied
the baseline distribution of patients over disease
states. In these three analyses, it was assumed that
at baseline, 100% of the patients were suffering
from moderate disease (SA6), severe disease (SA7),
and very severe disease (SA8), respectively. In sen-
sitivity analysis 9, alternative utility values were
assigned to disease states: moderate COPD 0.81
(SE: 0.02), severe COPD 0.72 (0.03), and very
severe COPD 0.67 (0.05) [23]. Because transitions
in the model were derived from patient-level data in
trials that included only stable patients who were
not using long-term oxygen at study entry, we did
not include the costs of oxygen therapy in our base-
case analysis. The effect of adding estimates of
oxygen use (Table 2) to the costs of maintenance
therapy was investigated in a ﬁnal sensitivity anal-
ysis (SA10).
 
Validation of the Model
 
To validate the exacerbation outcomes of the model
we compared these outcomes with the empiric anal-
yses of the trial data. To perform this validation, the
model was populated with the trial-speciﬁc baseline
distribution of patients over disease states, and trial-
speciﬁc transition and exacerbation probabilities.
This validation can only be performed pair-wise, as
each trial compared only two treatments. For the
comparison between tiotropium and salmeterol, the
time horizon of the model was set to 6 months to
match the duration of the trial. The exacerbation
rates obtained with the model were compared with
the empiric exacerbation rate based on an analysis
in which multiple imputations were used to account
for incomplete data because of dropout [24]. For
the ipratropium-controlled trials, these rates have
been published before [18], and for the salmeterol-
controlled trials, these rates are reported for the ﬁrst
time in this article.
 
Results
 
Health Outcomes
 
Table 3 summarizes the main outcomes of the
Markov model. Estimates of the mean (SE) number
of exacerbations varied from 0.85 (0.028) in the tio-
tropium group to 1.02 (0.095) in the salmeterol
group and 1.14 (0.125) in the ipratropium group.
The difference (95% UI) between tiotropium and
salmeterol was 0.17 (
 
-
 
0.02; 0.37) and the difference
between salmeterol and ipratropium was 0.12
(
 
-
 
0.17; 0.44). The proportion of exacerbations that
was severe varied from approximately 15% in the
tiotropium and salmeterol group to 20% in the
ipratropium group. Differences in quality-adjusted
life months were small and associated with wide
UIs. The mean (SE) number of quality-adjusted life
months varied from 8.42 (0.40) in the tiotropium
group to 8.17 (0.46) in the salmeterol group and
8.11 (0.49) in the ipratropium group.
 
Costs
 
Estimates of the mean (95% UI) 1-year cost per
patient in the Netherlands varied from 1760
 
€
 
(1563; 2011) in the tiotropium group to 1802
 
€
 
(1515; 2195) in the salmeterol group and 1930
 
€
 
Table 3
 
Results of  the Markov simulation*
 
Tiotropium Salmeterol Ipratropium
Number of  exacerbations
Nonsevere 0.73 (0.68; 0.78) 0.87 (0.71; 1.05) 0.91 (0.72; 1.14)
Severe 0.12 (0.10; 0.15) 0.15 (0.09; 0.21) 0.23 (0.15; 0.33)
Total 0.85 (0.80; 0.91) 1.02 (0.84; 1.22) 1.14 (0.92; 1.40)
Quality-adjusted life months 8.42 (7.59; 9.20) 8.17 (7.24; 9.06) 8.11 (7.08; 9.04)
Mean (SE) costs (in 2001 
 
€
 
) The 
Netherlands
Canada The Netherlands Canada The Netherlands Canada
Exacerbations
Hospitalizations 583 (112) 340 (43) 707 (166) 410 (88) 1004 (257) 646 (144)
Other exa-related costs 87 (7) 47 (3) 105 (13) 56 (6) 127 (17) 66 (8)
Subtotal exacerbations 670 (113) 387 (43) 812 (173) 466 (92) 1131 (266) 712 (144)
Maintenance therapy 517 (22) 371 (16) 537 (23) 398 (19) 547 (25) 398 (23)
Study medication 573 (–) 551 (–) 453 (–) 442 (–) 252 (–) 197 (–)
Total costs 1760 (116) 1309 (47) 1802 (175) 1306 (96) 1930 (267) 1307 (150)
95% UI of  total cost 1563; 2011 1222; 1408 1515; 2195 1142; 1516 1503; 2525 1050; 1637
Tiotropium vs. salmeterol Salmeterol vs. ipratropium
Difference in: The Netherlands Canada The Netherlands Canada
Costs (in 2001 €) -42 (-484; 353) 3 (-227; 203) -128 (-795; 457) -1 (-376; 323)
Exacerbations avoided 0.17 (
 
-
 
0.02; 0.37) 0.12 (
 
-
 
0.17; 0.44)
Quality-adjusted life months 0.25 (
 
-
 
0.90; 1.47) 0.06 (
 
-
 
1.26; 1.42)
 
*Mean and 95% UI unless stated otherwise.
Abbreviation: UI, uncertainty interval.
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(1503; 2525) in the ipratropium group. The corre-
sponding estimates of the mean total costs for Can-
ada were considerably lower and varied from 1309
 
€
 
(1222; 1408) for tiotropium, 1306
 
€
 
 (1142; 1516)
for salmeterol and 1307
 
€
 
 (1050; 1637) for ipratro-
pium. The costs of the study medication tiotropium
made up approximately 33% of the total costs in
the Netherlands and 42% of the total costs in Can-
ada. Salmeterol accounted for 25% and 24% of
total costs in the Netherlands and Canada, respec-
tively, whereas the costs of ipratropium contributed
to approximately 14% of total costs in both coun-
tries. The largest difference in costs between the two
countries was observed in the costs of exacerba-
tions. In the Netherlands these costs varied from
670
 
€
 
 (38% of the total costs) in the tiotropium
group to 812
 
€
 
 (45%) in the salmeterol group and
1131
 
€
 
 (59%) in the ipratropium group. The corre-
sponding estimates for Canada were 387
 
€
 
 (30%),
466 (36%), and 712
 
€ (54%), respectively.
Cost-Effectiveness
Figure 2 presents the uncertainty around the costs
and effects on the cost-effectiveness plane. To
reduce the number of ﬁgures, only the cost-
effectiveness planes comparing tiotropium to salm-
eterol are presented. Each dot represents one of the
5000 model simulations. The CE-planes show that
the uncertainty about costs in the Netherlands was
somewhat larger than in Canada. Dots were almost
evenly distributed over the upper and lower quad-
rants, showing the near cost-neutrality between tio-
tropium and salmeterol. The CE-planes also show
that there were no substantial differences between
treatment groups with regard to quality-adjusted
life months. In contrast, the difference in exacerba-
tions clearly was in favor of tiotropium. The pro-
portion of iterations in the right quadrants for this
outcome was approximately 95%.
In the Netherlands, the acceptability curves
(Fig. 3) representing quality-adjusted life months
show that the probability tiotropium is cost-
effective was almost independent of the value of the
ceiling ratio, reﬂecting the small differences for this
outcome in the 1-year time horizon. A much larger
impact of the value of the ceiling ratio was observed
in the acceptability curves regarding exacerbations
avoided. The probability for tiotropium to be cost-
effective in the Netherlands gradually increased
from 43% when the ceiling ratio was set to 0€ to
60% when the ceiling ratio was set to 500€. In Can-
ada, tiotropium had the highest probability of being
cost-effective when the ceiling ratio for avoiding an
exacerbation was above 160€ and the ceiling ratio
for gaining one quality-adjusted life month was at
least 120€. For lower values, ipratropium had the
highest probability of being cost-effective but was
not associated with the highest expected net beneﬁt
[22]. Salmeterol had the highest expected net beneﬁt
for values of the ceiling ratio until approximately
10€, whereas tiotropium had the highest expected
net beneﬁt for all values higher than 10€. Hence,
the cost-effectiveness acceptability frontier (not
shown), followed the salmeterol curve for values of
the ceiling ratio below 10€ and followed the tiotro-
pium curve for all values higher than 10€, signifying
that in Canada, tiotropium was the preferred treat-
ment in terms of cost per exacerbation avoided,
Figure 2 Cost-effectiveness planes of  the
difference in costs and effects of  tiotropium
versus salmeterol. Each dot represents 1 of
5000 model simulations. The horizontal axis
represents the difference in the number
of  exacerbations and quality-adjusted life
months, respectively.
Exacerbations Quality-adjusted life months
Tiotropium versus salmeterol
The Netherlands
-1500
-1000
-500
0
500
1000
1500
-3.0 -2.5 -2.0 -1.5 -1.0 -0.5 0.0 0.5 1.0 1.5 2.0 2.5 3.0
Tiotropium versus salmeterol
The Netherlands
-1500
-1000
-500
0
500
1000
1500
-0.5 -0.3 0.0 0.3 0.5 0.8 1.0
Tiotropium versus salmeterol
Canada
-1500
-1000
-500
0
500
1000
1500
-3.0 -2.5 -2.0 -1.5 -1.0 -0.5 0.0 0.5 1.0 1.5 2.0 2.5 3.0
Tiotropium versus salmeterol
Canada
-1500
-1000
-500
0
500
1000
1500
-0.5 -0.3 0.0 0.3 0.5 0.8 1.0
Oostenbrink et al.40
except for ceiling ratios below 10€. For an explana-
tion about acceptability curves and the acceptability
frontier in case of multiple treatments and skewed
distributions, we refer to Fenwick et al. [22].
Sensitivity Analysis
The results of the sensitivity analyses are presented
in Table 4. For each sensitivity analysis, the Table
shows the values of the ceiling ratio at which each
treatment has the maximum expected net beneﬁt.
Tiotropium showed the maximum expected net
beneﬁt for all values of the ceiling ratio when
probabilities were set relative to the salmeterol-
controlled trials (SA2), whereas the value of the ceil-
ing ratio for which tiotropium was associated with
the maximum expected net beneﬁt increased when
probabilities were set relative to the ipratropium-
controlled (SA1) and placebo-controlled trials
(SA3). Applying similar transition probabilities to
treatment groups (SA4) had a large impact on qual-
ity-adjusted life months. In the Netherlands, salm-
eterol was associated with maximum expected net
beneﬁt for values below 1080€, whereas in Canada
ipratropium had maximum expected net beneﬁt for
values below 1180€. The impact on exacerbations
was much less and tiotropium was associated with
maximum expected net beneﬁt for all values of the
ceiling ratio above 180€ in the Netherlands and
above 400€ in Canada. Sensitivity analysis 5 shows
that for exacerbations ipratropium was associated
with the maximum expected net beneﬁt for all val-
ues of the ceiling ratio below 8500€ in the Nether-
lands and below 11,000€ in Canada. In terms of
quality-adjusted life months, these values were
1120€ and 1340€, respectively. Changing the divi-
sion of patients over disease severity states (SA6–8)
showed divergent results. When all patients had
moderate disease at baseline, salmeterol showed the
maximum expected net beneﬁt in the Netherlands
for values of the ceiling ratio below 440€, whereas
ipratropium had the highest expected net beneﬁt for
low values of the ceiling ratio for both outcomes
when all patients had very severe disease at baseline.
Alternative utility values (SA9) did not change the
cost-effectiveness frontier as compared with the
base-case analysis, whereas adding the costs of oxy-
gen therapy to the costs of maintenance therapy
(SA10) favored tiotropium in both settings.
Validation of the Model
When the model was populated with the baseline
distribution of patients over disease states, and
exacerbation and transition probabilities from the
ipratropium-controlled trials, the mean (SE) num-
bers of exacerbations were exactly the same as
observed in the trials (tiotropium 0.74 (0.08), ipra-
tropium 1.01 (0.12)) [18]. Only the SE of ipratro-
pium was slightly larger (model 0.12, trials 0.10). A
comparison with the salmeterol-controlled trials
based on a 6-month time horizon showed that the
mean estimates of the model (tiotropium 0.69
(0.07), salmeterol 0.82 (0.09)) were somewhat
higher than observed in the trials (tiotropium 0.63
(0.06), salmeterol 0.76 (0.06)), but that the esti-
mated difference between treatment groups was
exactly the same, 0.13 (0.08).
Discussion
In this study, we showed how patient-level clinical
data could be used to construct a 1-year model to
Figure 3 Cost-acceptability curves of  exac-
erbations avoided and quality-adjusted life
months for the Netherlands and Canada.
Continuous line: tiotropium, line marked by
triangles: salmeterol, broken line: ipratro-
pium. In the Netherlands the cost-
effectiveness acceptability frontier follows
the tiotropium curves. In Canada, the cost-
effectiveness acceptability frontier follows
the salmeterol curves for values of  the ceiling
ratio below approximately 10€. For all values
higher than 10€ the frontier follows the
tiotropium curves, signifying the higher
expected net beneﬁt [22].
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compare the cost-effectiveness of three bronchodi-
lators in different countries. The model demon-
strated that tiotropium was associated with a
reduction of 17% in the number of exacerbations
when compared with salmeterol. When salmeterol
was compared with ipratropium, the number of
exacerbations was reduced by 11%. No substantial
differences in quality-adjusted life were found
between treatment groups in this 1-year model.
Overall, costs were considerably higher in the Neth-
erlands than in Canada, mainly because of the
higher costs associated with exacerbations. In the
Netherlands, tiotropium was associated with small
cost-reductions, whereas in Canada costs were
almost the same in all treatment groups. The cost-
effectiveness acceptability frontier of exacerbations
showed that tiotropium was associated with the
maximum expected net beneﬁt for all values of the
ceiling ratio above 0€ (the Netherlands) and 10€
(Canada) in the base-case analysis.
Our model was speciﬁcally developed to facili-
tate the process of adaptation of pharmacoeco-
nomic data to the local setting. Indeed, the
difference in results between the Netherlands and
Canada reﬂect differences in treatment patterns
between these countries. The ﬁnding that tiotro-
pium was somewhat more cost-effective in the
Netherlands than in Canada was largely driven by
the observation that the hospitalization cost per
exacerbation in the Netherlands was approximately
25% higher than in Canada, as a result of longer
length of stay. Hence, a reduction in the number of
exacerbation-related hospital admissions in patients
treated with tiotropium leads to considerably higher
savings in the Netherlands than in Canada, espe-
cially when considering the fact that the daily acqui-
sition cost of tiotropium hardly differs between the
two countries. Other differences between the two
countries were the lower use of antibiotics and sys-
temic steroids during exacerbations and the higher
number of emergency room visits in Canada. The
higher costs of maintenance therapy in the Nether-
lands are largely a result of the higher use of inhaled
steroids in all disease severity states.
An important characteristic of the model is that
all model inputs related to the effectiveness of treat-
ment are based on patient-level trial data of the tio-
tropium clinical trial program. This minimizes the
impact of different inclusion and exclusion criteria
as well as trial design features commonly compli-
cating across study comparisons. In addition, this
approach offers the possibility to test the internal
consistency of the model by comparing the model
outcomes with the results of the clinical trials. It
Table 4 Results of  the sensitivity analyses showing the values of  the ceiling ratio at which each treatment has the maximum
expected net beneﬁt (i.e., description of  the cost-effectiveness frontiers; in 2001 €)
Exacerbations avoided Quality-adjusted life months 
The Netherlands Canada The Netherlands Canada
Base-case Tiotropium: ≥0 Salmeterol: 0–9 Tiotropium: ≥0 Salmeterol: 0–9
Tiotropium: ≥10 Tiotropium: ≥10
SA 1 Salmeterol: 0–59 Ipratropium: 0–539 Salmeterol: 0–44 Ipratropium: 0–499
Tiotropium: ≥60 Tiotropium: ≥540 Tiotropium: ≥45 Tiotropium: ≥500
SA 2 Tiotropium: ≥0 Tiotropium: ≥0 Tiotropium: ≥0 Tiotropium: ≥0
SA 3 Salmeterol: 0–49 Salmeterol: 0–219 Salmeterol: 0–24 Salmeterol: 0–119
Tiotropium: ≥50 Tiotropium: ≥220 Tiotropium: ≥25 Tiotropium: ≥120
SA 4 Salmeterol: 0–179 Ipratropium: 0–379 Salmeterol: 0–1079 Ipratropium: 0–1179
Tiotropium: ≥180 Salmeterol: 380–399 Tiotropium: ≥1080 Salmeterol: 1180–2719
Tiotropium: ≥400 Tiotropium: ≥2720
SA 5 Ipratropium: 0–8499 Ipratropium: 0–10999 Ipratropium: 0–1119 Ipratropium: 0–1339
Tiotropium: ≥8500 Tiotropium: ≥11000 Tiotropium: ≥1120 Tiotropium: ≥1340
SA 6 Salmeterol: 0–439 Tiotropium: ≥0 Salmeterol: 0–399 Tiotropium: ≥0
Tiotropium: ≥440 Tiotropium: ≥400
SA 7 Tiotropium: ≥0 Tiotropium: ≥0 Tiotropium: ≥0 Tiotropium: ≥0
SA 8 Ipratropium: 0–339 Ipratropium: 0–779 Ipratropium: 0–159 Ipratropium: 0–359
Tiotropium: ≥340 Tiotropium: ≥780 Tiotropium: ≥160 Tiotropium: ≥360
SA 9 Tiotropium: ≥0 Salmeterol: 0–9 Tiotropium: ≥0 Salmeterol: 0–9
Tiotropium: ≥10 Tiotropium: ≥10
SA 10 Tiotropium: ≥0 Tiotropium: ≥0 Tiotropium: ≥0 Tiotropium: ≥0
SA 1, sensitivity analysis 1: transition and exacerbation probabilities relative to those observed in the trials comparing tiotropium with ipratropium.
SA 2, transition and exacerbation probabilities relative to those observed in the trials comparing tiotropium with salmeterol.
SA 3, transition and exacerbation probabilities relative to those observed in the trials comparing tiotropium with placebo.
SA 4, similar transition probabilities in all treatment groups (probabilities equal those of  ipratropium in the base-case analysis).
SA 5, similar exacerbation probabilities in all treatment groups (probabilities equal those of  ipratropium in the base-case analysis).
SA 6 to SA 8, 100% of  the patients at baseline in moderate, severe, and very severe disease, respectively.
SA 9, alternative utility weights per disease state, mean (SE): moderate 0.81 (0.02), severe 0.72 (0.03), very severe 0.67 (0.05) [23].
SA 10, use of  oxygen therapy added to the costs of  maintenance therapy.
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was shown that the model closely resembled the dif-
ference in the numbers of exacerbations that were
observed in the original trials. The ability to com-
pare the outcomes of the model with the original
trial data makes the model transparent and may
thereby increase the acceptance of this model by
local reimbursement authorities.
Limitations of this approach are that other avail-
able data about the efﬁcacy of the existing treat-
ments, ipratropium and salmeterol, are not
considered and that the outcomes of the model are
based on the speciﬁc design of the tiotropium stud-
ies. More research is needed to formally integrate all
available evidence on the effects of bronchodilator
therapy in COPD on exacerbations in meta-
analyses, and then modeling their cost-effectiveness
to provide further information for medical decision
making. This is, however, complicated by the lack
of a uniform deﬁnition of exacerbations [25].
In accordance with clinical guidelines, lung func-
tion parameters were used to classify patients into
disease severity states [1]. Two recently published
models in COPD also used this disease classiﬁcation
[15,26]. Because COPD is increasingly recognized
as being a multifaceted disease that not only impairs
lung function, but also has systematic conse-
quences, in the future, it may become common
practice to determine disease severity based on a
combination of variables. For instance, Celli et al.
constructed a multidimensional grading system,
based on FEV1, 6-minute walk test result, dyspnea
assessment, and body mass index [27]. They
showed that this so-called BODE index is better
than FEV1 at predicting mortality. Because this
index was only recently proposed, the classiﬁcation
has not been used in the clinical trials underlying the
current model.
In the GOLD guidelines, the classiﬁcation into
disease states is based on postbronchodilator FEV1,
whereas in the model disease classiﬁcation was
based on prebronchodilator values (trough FEV1)
because postbronchodilator values at baseline (i.e.,
before the start of study medication) were not avail-
able. The trials showed that other lung function
parameters like peak FEV1 and the area under the
curve of 0–3 hours postbronchodilation as well as
the forced vital capacity were also consistently bet-
ter in the tiotropium group [11,13]. Because we
have used prebronchodilator values for all treat-
ments, where lung function measurements were
done 24 hours after the last dose of tiotropium,
12 hours after the last dose of salmeterol and
6 hours after the last dose of ipratropium (i.e., at
the end of each recommended dosing interval),
there is no reason to belief that the use of prebron-
chodilator values has favored tiotropium over other
treatments. In addition, sensitivity analyses 4 and 5
have shown that exacerbation probabilities were
the main driver of the cost-effectiveness in terms of
exacerbations avoided and that the impact of dif-
ferences in disease state transitions in this 1-year
model was limited.
Our model is a short-term model that is not
intended to reﬂect the lifetime disease progression
of COPD. This explains why we did not model the
impact of mortality and smoking. In this study, out-
comes were measured in terms of exacerbations
avoided and quality-adjusted life months (EQ-5D).
The outcome parameter exacerbations closely
reﬂect the primary aim of the currently available
medical treatment options in COPD, which is
relieving symptoms and preventing exacerbations of
the disease [1]. Together with FEV1 it is the outcome
measure most often used in clinical studies in COPD
of this duration. Other economic evaluations in
asthma and COPD also adopted exacerbations or
related outcome measures like exacerbation-free
months or symptom-free days, as a primary out-
come measure [28,29]. The EQ-5D was not admin-
istered in the tiotropium trials and utilities
according to disease states and exacerbations had to
be derived from literature. Data about utility values
in patients with COPD was limited and we only
found two studies reporting EQ-5D values accord-
ing to disease severity [15,23]. These data and other
studies reporting on disease-speciﬁc quality of life
suggest that the relationship between disease sever-
ity and quality of life is not very strong and that
reductions in quality of life become most apparent
in patients with an FEV1% predicted below 50%.
To date, pharmaceutical treatments have not been
able to demonstrate an important effect on quality-
adjusted life-years in patients with COPD, hence,
we were not surprised to ﬁnd no effect in this 1-year
model either. Varying the utility weights (SA9) did
not change these ﬁndings.
As there was no head-to-head comparison of all
three treatments in the same trial, data from the tri-
als were combined. This was facilitated by the sim-
ilar study protocols of all tiotropium trials. For
probabilities in the tiotropium arm we simply
pooled the trials together. To obtain the data for
ipratropium and salmeterol, we applied the relative
difference between tiotropium and the two compa-
rators as observed in the individual trials to the
pooled data of tiotropium. There are other options,
such as taking the absolute difference or simply
using the transition and exacerbation probabilities
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as they were observed in the ipratropium and salm-
eterol arms of the trials. The latter option was
rejected, because of differences in the exacerbation
rate between the trials. When probabilities were
based on the salmeterol-controlled trials (SA2), the
number of exacerbations was almost twice as high
as in the analysis in which probabilities were based
on the ipratropium-controlled trials (SA1). Addi-
tional analyses showed that this difference in exac-
erbation rates between the trials was not related to
patient-characteristics or the difference in the dura-
tion of the trial. Hence, using the combined proba-
bilities for tiotropium and using the relative
difference of tiotropium to the other treatments
most accurately reﬂects the differences between
treatments that were actually observed.
This probabilistic model-based economic evalu-
ation demonstrates how clinical trial data can be
combined and integrated with country-speciﬁc
information about resource utilization and unit cost
in order to assess the cost-effectiveness of bron-
chodilators in COPD patients. Quality-adjusted life
months did not substantially differ between treat-
ment groups. In terms of exacerbations, tiotropium
was associated with maximum expected net beneﬁt
for plausible values of the ceiling ratio. In sensitivity
analyses, this outcome was most sensitive to
changes in exacerbation rates.
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Appendix: The Calculation of  Transition and 
Exacerbation Probabilities
Transition Probabilities
Probabilities to transition between disease severity
states were based on observed data from the clinical
trials. The calculation consisted of the following
steps:
1. Prebronchodilator FEV1 was measured at
baseline and regularly thereafter during sched-
uled follow-up visits. Based on these measure-
ments patients were classiﬁed into disease
states at each visit.
2. The difference between the frequency distribu-
tion of patients over disease states at baseline
and the ﬁrst visit was used to calculate the
transition probabilities for the ﬁrst cycle. The
difference between the frequency distribution
at the ﬁrst and last visit was used to calculate
transition probabilities for the remaining
cycles.
3. The time between baseline and the ﬁrst visit
was 8 days in the ipratropium- and placebo-
controlled trials and 15 days in the salme-
terol-controlled trials. In addition, the time
between the ﬁrst visit and last visit in the ipra-
tropium-, salmeterol- and placebo-controlled
trials was 356, 161, and 336 days, respec-
tively. Because the length of the ﬁrst cycle in
the model was set to 8 days and the length of
the remaining cycles was set to 1 month,
probabilities had to be recalculated into prob-
abilities covering an 8-day (ﬁrst cycle) and 1-
month (subsequent cycles) period.
4. The recalculation of probabilities in case of
multiple transitions from a single state is not
straightforward and involves a difﬁcult choice
among several possible nth root solutions of
the transition matrix [30]. In the current
study, we obtained a solution for the transi-
tion matrix using a Taylor series expansion as
described in the last part of this appendix.
This step resulted in transition matrices con-
taining 8 days (ﬁrst cycle) and 1 month
(subsequent cycles) probabilities. Separate
matrices were available for each treatment
group by trial (i.e., three sets of transition
matrices for tiotropium based on the ipratro-
pium-, salmeterol- and placebo-controlled
trials, a set of transition matrices for ipratro-
pium and a set of transition matrices for
salmeterol).
5a. To combine the data from the trials the tran-
sition probabilities for patients treated with
tiotropium were based on the average of three
matrices weighted by the number of tiotro-
pium patients. For instance, the probability to
transition from moderate to severe COPD for
patients treated with tiotropium during the
ﬁrst 8 days was 0.107 in the ipratropium-con-
trolled trials, 0.095 in the salmeterol-control-
led trials, and 0.080 in the placebo-controlled
trials. The numbers of patients treated with
tiotropium in these trials were 344, 402, and
550, respectively. Hence, the combined prob-
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ability to remain in the moderate state during
the ﬁrst cycle was calculated as:
(344 ¥ 0.107 + 402 ¥ 0.095 + 550 ¥ 0.080)/
(344 + 402 + 550) = 0.092.
5b. The transition probabilities for patients
treated with ipratropium and salmeterol were
based on the relative differences in transition
probabilities as found in the trials. These rel-
ative differences are multiplied with the corre-
sponding probabilities calculated at step 5a.
For instance, in the ipratropium-controlled tri-
als it was found that the probability for a
patient with moderate COPD in the tiotro-
pium and ipratropium group to transition to
severe COPD during the ﬁrst 8 days was 0.107
and 0.291, respectively. Hence, the relative
probability for ipratropium compared with
tiotropium was 0.291/0.107 = 2.72. Finally,
the probability for patients treated with ipra-
tropium to transition from moderate to severe
COPD was calculated as 2.72 times 0.092 is
0.257.
6. Standard errors of the probabilities deter-
mined in step 5 were calculated as (P ¥ (1 -
 P)/N)1/2, where P is the probability to transi-
tion between two disease states and N the
original number of patients in the disease
state at the start of the interval. For instance,
the probability to transition from moderate to
severe COPD for patients treated with iprat-
ropium was calculated as 0.257 and the
number of patients with moderate disease in
the ipratropium group at baseline was 23.
Hence, the SE was calculated as (0.257 ¥ (1 -
 0.257)/23)1/2 = 0.091.
7. The resulting sets of transition parameters are
presented in Table 1. A Dirichlet distribution
[14] was assigned to these input parameters
and a Monte Carlo simulation was performed
in which values were randomly drawn from
these distributions. Parameters of the Dirich-
let distribution are the numbers of patients
transitioning between disease states. For ease
of interpretation this table presents the
expected values (probabilities) and the associ-
ated standard errors rather than these num-
bers. Probabilities can be recalculated into
numbers using method-of-moments ﬁtting
[20].
Exacerbation Probabilities
1. The number of months patients remained in
each disease state and the number of exacer-
bations experienced while being in a particular
disease state were collected from the clinical
trial data.
2a. The number of exacerbations and months per
disease state for tiotropium were summed over
all three trials. For instance, the number of
exacerbations experienced by patients in the
tiotropium group, while being in a moderate
disease state was 68.6, 44.1, and 93.4 in the
ipratropium-, salmeterol- and placebo-
controlled trials, respectively. The total
number of months patients remained in the
moderate disease state was 1469, 689 and
1856, respectively. Hence, the total number of
exacerbations for patients treated with tiotro-
pium in the moderate disease state was 206.1
and the total number of months was 4014, an
overall probability of 0.051.
2b. To calculate the input parameters for ipratro-
pium and salmeterol we ﬁrst calculated (for
each disease state separately) the trial-speciﬁc
exacerbation probability for the comparator
relative to tiotropium. This relative probabil-
ity was then multiplied with the overall prob-
ability for tiotropium (as calculated at 2a). For
instance, the trial-speciﬁc exacerbation proba-
bilities for patients in the moderate disease
state treated with tiotropium and ipratropium
were 0.0467 (68.6 exacerbations in
1469 months) and 0.0733 (23.4 exacerba-
tions in 319 months), respectively. The rela-
tive probability of ipratropium compared to
tiotropium was 0.0733/0.0467 is 1.568. This
relative probability is multiplied with the
overall probability for tiotropium of 0.051 is
0.080.
2c. To estimate the SE of the probabilities calcu-
lated at 2b, we performed simple simulations
based on 5000 iterations. Input parameters
were the number of exacerbations and months
for tiotropium and the comparator (ipratro-
pium or salmeterol) as observed in the trials
and the corresponding numbers for the com-
bined tiotropium data (as calculated at step
2a). In all iterations, probabilities were ran-
domly drawn from beta distributions with
these parameters. Hence, each iteration
resulted in a probability for the tiotropium arm
(trial-speciﬁc; A) the comparator-arm (B) and
the combined tiotropium arm (C). The prob-
ability of the comparator relative to tiotropium
(D) was calculated as B divided by A, and the
new probability for the comparator (E) as C
times D. The SE is now calculated as the stand-
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ard deviation of E of the 5000 iterations. A sep-
arate simulation was performed for every SE.
Taylor series expansion for the calculation of
period-speciﬁc transition probabilities. To calcu-
late the transition probability per model cycle, we
invoke the assumptions of a Markov chain and
assume that there is a short-term improvement in
disease status within the ﬁrst 8 days immediately
following the initiation of treatment. Thereafter,
disease progression is assumed to be constant over
time. Mathematically, these assumptions can be rep-
resented by the equations
N1  =  P1TN0
for the ﬁrst period and
Nk  =  PkTNk-1
for the subsequent periods, where N0 is a vector rep-
resenting the initial distribution of patients over dis-
ease state, Nk is a vector depicting the distribution
in period k, P1 is the transition matrix for the ﬁrst
period (transposed as denoted by the superscript
“T”) and Pk the transition matrix for the following
periods. These equations can be combined because
N1  =  P1TN0
N2  =  P2TN1  =  P2TP1TN0
N3  =  P2TN2  =  P2TP2TP1TN0  =  (P2T)2P1TN0
Etc.
Thus Nk = (P2T)k-1 P1T N0 for k = 1, 2, 3, . . .
Under these assumptions, we can calculate the
period-speciﬁc transition probability matrices to be
used in the model. These are based on a Taylor
Series expansion.
Taylor Series in one variable.
Many (but not all) functions f(x) may be repre-
sented by a power series of the form
f(x)  =  f(a)  +  f(1)(a)(x  -  a)/1!  +  f(2)(a)(x  -  a)2/
2!  +  f(3)(a)(x  -  a)3/3!  +  . . .  +  f(n)(a)(x  -  a)n/
n!  +  . . .
where a is a point of interest to the investigator,
f(k)(a) is the k’th derivative of f(x) evaluated at a and
k! is the factorial function (k! = k(k - 1)
(k - 2). . .(3)(2)(1)).
Not unusually, the point a of interest is 0. In that
case, the Taylor Series reduces to a Maclaurin
Series, namely
f(x)  =  f(0)  +  f(1)(0) x/1!  +  f(2)(0) x2/2!  +  f(3)(0) 
x3/3!  +  . . .  +  f(n)(0) xn/n!  +  . . .
The series relevant to this study is the binomial
series which relates to the function (1 + x)b (where b
is some number, not necessarily either positive or
integer). The Maclaurin expansion for this function
is
(1  +  x)b  =  1  +  bx/1!  +  b(b  -  1)x2/2!  +  b
(b  -  1)(b  -  2)x3/3!  +  . . .
The corresponding function for (1 - x)b is
(1  -  x)b  =  1  -  bx/1!  +  b(b  -  1)x2/2!  -
b(b  -  1)(b  -  2)x3/3!  +  . . .
This expression does not converge for all values
of x. For a univariate function, the series converges
on the range -1 £ x £ 1 if b > 0 but is not an integer.
Such an expansion may also hold for functions of
matrices. In this study, we observe a transition
matrix for a given period, e.g., 6 months. For the
purposes of modeling, this may not be directly use-
ful as we may wish to work at a shorter time period.
In other words, we are interested in functions such
as A1/n for some value of n. For example, suppose
we have a matrix P2mo which represents the transi-
tion probabilities associated with a 2 months period
and that we wish to estimate the transition proba-
bility matrix associated with a 1-month period,
assuming the Markov property. If we denote that
probability matrix by P1mo then by the Markov
assumption
P2mo  =  P1mo P1mo  =  (P1mo)2
In other words,
P1mo  =  P2mo1/2
If we observe P2mo (but not P1mo), we can estimate
P1mo by
(I  -  (I  -  P2mo))1/2  =  I  -  1/2(I  -  P2mo)/1!  +
1/2(1/2  -  1)(I  -  P2mo)2/2!  -  1/2(1/2  -  1)(1/2  -  2) 
(I  -  P2mo)3/3!  +  . . .
since P1mo = P2mo1/2 = (I - (I - P2mo))1/2 where I is the
identity matrix. The question remains as to under
what conditions this expansion will converge. It is
known that the largest eigenvalue of a transition
matrix is equal to 1. Therefore, the spectral radius
of a transition matrix will be equal to 1 and the
series will converge. Thus, we can estimate a bino-
mial function of a matrix, provided it converges. Of
course, the expansion has to be truncated at some
ﬁnite level. This, and other small errors associated
with the calculation process may lead to small neg-
ative elements in the solution matrix. If this situa-
tion arises, the simplest solution is to set the
negative element to 0 and adjust the positive ele-
ments accordingly.
